Suven Life Sciences Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant, an α4β2 Antagonist representing a Novel Mechanism of Action for the treatment of Major Depressive Disorder".